Moderna’s mRNA Vaccine Candidate Prevents RSV-Associated Disease in Older Adults
Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.
Diagnosis & Disease Information
Nirsevimab Under Review for Protection Against RSV for All Infants
Nirsevimab is a long-acting anti-RSV for nirsevimab for the prevention of RSV lower.
RSV Surge: Bigger, Earlier, and Older Than Previous Seasonal Outbreaks
Although this year’s ultra-high rates of RSV hospitalizations have recently fallen, certain features of this season’s outbreak set it apart from those of previous years.
- Loading...
Loading...
Loading... 
Loading...